Charles Prince - Johnson Johnson Independent Director

<div class='circular--portrait' style='background:#4E8BFC;color: #ffffff;font-size:4em;padding-top: 25px;;'>JJ</div>
JNJ -- USA Stock  

 Earnings Call  This Week

  Director
Mr. Charles O. Prince, III. J.D, is an Independent Director of the Company. Mr. Prince served as Chief Executive Officer of Citigroup Inc. from 2003 to 2007 and as Chairman from 2006 to 2007. Previously he served as Chairman and Chief Executive Officer of Citigroups Global Corporationrationrate and Investment Bank from 2002 to 2003 and Chief Operating Officer from 2001 to 2002, and held positions of increasing responsibility since joining Commercial Credit Company, a predecessor to Citigroup, in 1979. Mr. Prince began his career as an attorney at U.S. Steel Corporationrationration in 1975. Mr. Prince is a member of the Council on Foreign Relations and The Council of Chief Executives.
Age: 69  Director Since 2006      
732 214-0332  www.jnj.com

Charles Prince Latest Insider Activity

Johnson Johnson Management Efficiency

Johnson Johnson has Return on Asset of 8.83 % which means that on every $100 spent on asset it made $8.83 of profit. This is considered to be average in the sector. In the same way, it shows return on shareholders equity (ROE) of 28.55 %, implying that it generated $28.55 on every 100 dollars invested. Johnson Johnson management efficiency ratios could be used to measure of how well the company is managing its routine affairs as well as how well it utilizes its assets and manages liabilities. Johnson Johnson Return on Investment is decreasing as compared to previous years. The last year's value of Return on Investment was reported at 19.14. The current Return on Average Assets is estimated to increase to 0.009237, while Return on Invested Capital is estimated to decrease to 0.29. Johnson Johnson Net Current Assets as percentage of Total Assets are decreasing as compared to previous years. The last year's value of Net Current Assets as percentage of Total Assets was reported at 7.98. The current Return on Average Assets is estimated to increase to 0.009237, while Tax Assets are estimated to decrease to under 6.8 B. Johnson Johnson Current Liabilities is increasing as compared to previous years. The last year's value of Current Liabilities was reported at 30.54 Billion. The current Tax Liabilities is estimated to increase to about 20.2 B, while Total Liabilities is estimated to decrease to under 90.3 B.
The company has 27.58 B in debt with debt to equity (D/E) ratio of 0.45, which is OK given its current industry classification. Johnson Johnson has a current ratio of 1.28, demonstrating that it may not be capable to disburse its financial commitments when the payables are due.

Similar Executives

Showing few of many executives

DIRECTOR Since

Michael EskewEli Lilly And
2008
Gerald StorchBristol Myers Squibb
2012
Catherine MackeyGW Pharmaceuticals Plc
2017
Christopher ToveyGW Pharmaceuticals Plc
2012
Tim JacksonSmithAstrazeneca PLC
2015
Rochelle LazarusMerck Company
2004
Iain MackayGlaxoSmithKline PLC
2019
Ellen MarramEli Lilly And
2013
Jesse GoodmanGlaxoSmithKline PLC
2017
Theodore SamuelsBristol Myers Squibb
2017
Michael GrobsteinBristol Myers Squibb
2007
Bruce BurlingtonAstrazeneca PLC
2010
Robert BertoliniBristol Myers Squibb
2017
Richard WhitleyGilead Sciences
2008
Daniel PodolskyGlaxoSmithKline PLC
2006
Gayle WilsonGilead Sciences
2001
Andreas PlantaNovartis AG
2006
William WaldegraveGW Pharmaceuticals Plc
2017
Cornelia BargmannAstrazeneca PLC
2015
Pamela CraigMerck Company
2015
Baroness VaderaAstrazeneca PLC
2011

Company Summary

Johnson Johnson researches and develops, manufactures, and sells various products in the health care field worldwide. The company was founded in 1886 and is based in New Brunswick, New Jersey. Johnson Johnson operates under Drug ManufacturersGeneral classification in the United States and is traded on BATS Exchange. It employs 132200 people.Johnson Johnson (JNJ) is traded on BATS Exchange in USA. It is located in One Johnson and Johnson Plaza, New Brunswick, NJ 08933, United States and employs 132,200 people. Johnson Johnson is listed under Pharmaceutical Products category by Fama And French industry classification.

Johnson Johnson Leadership Team

A Washington, Independent Director
Jennifer Doudna, Independent Director
Alex Gorsky, Chairman, CEO, Chairman of Executive Committee and Chairman of Fin. Committee
William Perez, Independent Director
Michael Sneed, Executive Vice President - Global Corporate Affairs and Chief Communication Officer
Marillyn Hewson, Independent Director
Jorge Mesquita, Executive Vice President Worldwide Chairman - Consumer
Mary Coleman, Independent Director
Michael Ullmann, VP, General Counsel and Member of Executive Committee
Joaquin Duato, Executive Vice President Worldwide Chairman - Pharmaceuticals
Kathy Wengel, Executive Vice President Chief Global Supply Chain Officer
Jennifer Taubert, Executive Vice President - Worldwide Chairman, Pharmaceuticals
Mary Beckerle, Independent Director
Sandra Peterson, Group Worldwide Chairman and Member of Executive Committee
Scott Davis, Director
Louise Mehrotra, Vice President Investor Relations
Ashley McEvoy, Executive Vice President - Worldwide Chairman, Medical Devices
Ronald Williams, Independent Director
Kathryn Wengel, Executive Vice President Chief Global Supply Chain Officer
D Davis, Independent Director
Hubert Joly, Independent Director
Anne Mulcahy, Lead Independent Director
Joseph Wolk, Chief Financial Officer, Executive Vice President
Thibaut Mongon, Executive Vice President Worldwide Chairman, Consumer
Ian Davis, Independent Director
Paulus Stoffels, Worldwide Chairman of Pharmaceuticals, Chief Scientific Officer and Member of Executive Committee
Mark McClellan, Independent Director
Charles Prince, Independent Director
Eugene Washington, Independent Director
Dominic Caruso, CFO, VP of Fin. and Member of Executive Committee
Peter Fasolo, Chief Human Resource Officer, Executive Vice President
Susan Lindquist, Independent Director
Mark Weinberger, Independent Director

Stock Performance Indicators

Current Sentiment - JNJ

Johnson Johnson Investor Sentiment

Predominant part of Macroaxis users are currently bullish on Johnson Johnson. What is your judgment towards investing in Johnson Johnson? Are you bullish or bearish?
Bullish
Bearish
98% Bullish
2% Bearish
Skip

Build Optimal Portfolios

Align your risk with return expectations

Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Please see Risk vs Return Analysis. Please also try Portfolio Anywhere module to track or share privately all of your investments from the convenience of any device.
Macroaxis is not a registered investment advisor or broker/dealer. All investments, including stocks, funds, ETFs, or cryptocurrencies, are speculative and involve substantial risk of loss. We encourage our investors to invest carefully. Much of our information is derived directly from data published by companies or submitted to governmental agencies which we believe are reliable, but are without our independent verification. Therefore, we cannot assure you that the information is accurate or complete. We do not in any way warrant or guarantee the success of any action you take in reliance on our statements or recommendations. Also, note that past performance is not necessarily indicative of future results. All investments carry risk, and all investment decisions of an individual remain the responsibility of that individual. There is no guarantee that systems, indicators, or signals will result in profits or that they will not result in losses. All investors are advised to fully understand all risks associated with any investing they choose to do. Hypothetical or simulated performance is not indicative of future results. We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown because hypothetical or simulated performance is not necessarily indicative of future results. For more information please visit our terms and condition page